



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

JW

JFW 1624

Dennis A. Carson et al.

Title: INDOLE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER

Docket No.: 103.022US1

Serial No.: 09/634,207

Filed: August 9, 2000

Due Date: N/A

Examiner: Tamthom M. Truong

Group Art Unit: 1624

MS Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

We are transmitting herewith the following attached items (as indicated with an "X"):

Return postcard.
 Supplemental Information Disclosure Statement (2 pgs.), Form 1449 (1 pg.), and copies of 5 cited documents.

If not provided for in a separate paper filed herewith, Please consider this a PETITION FOR EXTENSION OF TIME for sufficient number of months to enter these papers and please charge any additional fees or credit overpayment to Deposit Account No. 19-0743.

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
Customer Number 21186

By: Mohique M. Perdok Shonka
Atty: Mohique M. Perdok Shonka
Reg. No. 42,989

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 30 day of January, 2006.

JAMES KAUYSIK
Name

James Kauysik
Signature

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
(GENERAL)

S/N 09/634,207



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Dennis A. Carson et al. Examiner: Tamthom M. Truong
Serial No.: 09/634,207 Group Art Unit: 1624
Filed: August 09, 2000 Docket: 103.022US1
Title: INDOLE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicant respectfully requests that this Supplemental Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicant requests that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicant with the next official communication.

Pursuant to 37 C.F.R. §1.97(b), it is believed that no fee or statement is required with the Supplemental Information Disclosure Statement. However, if an Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge the required fees to Deposit Account No. 19-0743 in order to have this Supplemental Information Disclosure Statement considered.

Pursuant to 37 C.F.R. 1.98(a)(2), Applicant believes that copies of cited U.S. Patents and Published Applications are no longer required to be provided to the Office. Notification of this change was provided in the United States Patent and Trademark Office OG Notices dated October 12, 2004. Thus, Applicant has not included copies of any U.S. Patents or Published Application cited with this submission. Should the Office require copies to be provided, Applicant respectfully requests that notice of such requirement be directed to Applicant's below-signed representative. Applicant acknowledges the requirement to submit copies of foreign patent documents and non-patent literature in accordance with 37 C.F.R. 1.98(a)(2).

The Examiner is invited to contact the Applicant's Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,

DENNIS A. CARSON ET AL.

By their Representatives,


SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(612) 373-6905


Date Jan 30, 2006

By Monique M. Perdot Shonka
Monique M. Perdot Shonka
Reg. No. 42,989

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 30 day of January, 2006.

JAMES KARUSIK
Name


Signature

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(Use as many sheets as necessary)</small>		Application Number <u>09/634,207</u> Filing Date <u>August 9, 2000</u> First Named Inventor <u>Carson, Dennis</u> Group Art Unit <u>1624</u> Examiner Name <u>Truong, Tamthom</u>	
 Sheet 1 of 1		Attorney Docket No: 103.022US1	

US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date If Appropriate
	US-2005/0239752A1	10/27/2005	Carson, D. A., et al.	12/16/2004
	US-4,041,169	08/09/1977	Demerson, Christopher A., et al.	10/28/1976
	US-4,179,503	12/18/1979	Asselin, Andre A., et al.	05/08/1978
	US-5,780,435	07/14/1998	Garnick, M. B., et al.	12/15/1995
	US-6,300,313	10/09/2001	Engel, J., et al.	09/22/1999

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	T ²
	CA-1299577	04/28/1992	Guindon, Yvan , et al.	
	GB-1436893	05/26/1976	, et al.	
	WO-02/02125A1	01/10/2002	Tait, Russell , et al.	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		KOLLURI, S. K., et al., "The R-Enantiomer of the Nonsteroidal Antiinflammatory Drug Etodolac Binds Retinoid X Receptor and Induces Tumor-Selective Apoptosis", Proc. Natl. Acad. Sci. USA., 102(7), (2005), 2525-2530	
		MYCEK, M. J., et al., "Anticancer Drugs", Lippincott's Illustrated Reviews: Pharmacology, Second Edition, (1997),373; 387-395	

EXAMINER

DATE CONSIDERED